Drug Trial Radar · NCT04309474
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Nov 9, 2020
Primary completion
Apr 18, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants following an acute ischemic stroke. Elezanumab is an investigational drug being developed for the treatment of acute ischemic stroke. This 52-week study is "double-blinded', which means that neither the participants nor the study doctors will know who will be given elezanumab and who will be given placebo (does not contain treatment drug). Participants will be assigned to one of two groups, called treatment arms. Participants in one arm will receive elezanumab and participants in the other arm will receive placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 120 subjects will be enrolled in 45 sites worldwide. Participants will be randomized to elezanumab or placebo by intravenous (IV) infusion within 24 hours of "last known normal" (time when the participant was last known to be without signs and symptoms of the current stroke) and every 4 weeks thereafter for 48 weeks for a total of 13 doses. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of elezanumab will be checked by medical assessments, blood tests, evaluation of side effects, and completion of questionnaires.
Conditions
- Acute Ischemic Stroke
Interventions
ElezanumabDrug
Intravenous (IV) infusion
PlaceboDrug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment PeriodTime frame: Day 1 through Week 52
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona /ID# 214957
Phoenix, Arizona
Long Beach Medical Center /ID# 217210
Long Beach, California
Georgetown University Hospital /ID# 216481
Washington D.C., District of Columbia
Duplicate_Mayo Clinic /ID# 217567
Jacksonville, Florida
Northwestern University Feinberg School of Medicine /ID# 215047
Chicago, Illinois
Duplicate_University of Kentucky Chandler Medical Center /ID# 216394
Lexington, Kentucky
University of Louisville Hospital /ID# 217569
Louisville, Kentucky
Tufts Medical Center /ID# 215053
Boston, Massachusetts
University of Mississippi Medical Center /ID# 217587
Jackson, Mississippi
St. Luke's Marion Bloch Neuroscience Institute /ID# 215028
Kansas City, Missouri
Washington University-School of Medicine /ID# 214526
St Louis, Missouri
Hackensack Univ Med Ctr /ID# 218200
Hackensack, New Jersey
University of New Mexico School of Medicine /ID# 216827
Albuquerque, New Mexico
Columbia University Medical Center /ID# 215122
New York, New York
UH Cleveland Medical Center /ID# 215372
Cleveland, Ohio
Cleveland Clinic Main Campus /ID# 214635
Cleveland, Ohio
The Ohio State University /ID# 215036
Columbus, Ohio
Lehigh Valley Health Network /ID# 242446
Allentown, Pennsylvania
Thomas Jefferson University Hospital /ID# 215469
Philadelphia, Pennsylvania
University of Texas Health Science Center at Houston /ID# 215018
Houston, Texas
Baylor Scott & White Medical Center- Temple /ID# 225513
Temple, Texas
University of Virginia /ID# 215757
Charlottesville, Virginia
Duplicate_Royal North Shore Hospital /ID# 239083
St Leonards, New South Wales, Australia
The Royal Melbourne Hospital /ID# 240178
Parkville, Victoria, Australia
University of Alberta Hospital /ID# 218370
Edmonton, Alberta, Canada
Hamilton General Hospital /ID# 218970
Hamilton, Ontario, Canada
Fukuoka University Chikushi Hospital /ID# 240629
Chikushino-shi, Fukuoka, Japan
Fukuoka Wajiro Hospital /ID# 239810
Fukuoka, Fukuoka, Japan
National Hospital Organization Kagoshima Medical Center /ID# 240021
Kagoshima, Kagoshima-ken, Japan
Nagano Municipal Hospital /ID# 240622
Nagano, Nagano, Japan
Yamaguchi Grand Medical Center /ID# 239892
Hohu-shi, Yamaguchi, Japan
Duplicate_Pusan National University Hospital /ID# 233769
Busan, Busan Gwang Yeogsi, South Korea
Duplicate_CHA University Bundang Medical Center /ID# 233503
Seongnam-si, Gyeonggido, South Korea
Seoul National University Hospital /ID# 233473
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center /ID# 234241
Seoul, Seoul Teugbyeolsi, South Korea
Hospital Universitario Vall de Hebron /ID# 217087
Barcelona, Spain
Hospital Universitario La Paz /ID# 216380
Madrid, Spain
Hospital Universitario Virgen Macarena /ID# 216382
Seville, Spain
Hospital Universitario Virgen del Rocio /ID# 216339
Seville, Spain
Complejo Hospitalario Universitario A Coruña /ID# 230080
A Coruña, A Coruna, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.